Trial Profile
A Randomized Phase II Trial Assessing Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors After Failure of All Drugs Known to be Effective
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Sorafenib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms NEXIRI 2-PRODIGE 27; NEXIRI-2
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
- 23 Jan 2016 Status changed from recruiting to completed as result presented at the 2016 Gastrointestinal Cancers Symposium
- 03 Dec 2012 New trial record